Nuvectis Pharma, Inc. (NVCT)
NASDAQ: NVCT · Real-Time Price · USD
8.40
+0.03 (0.36%)
Jan 29, 2026, 1:30 PM EST - Market open
Nuvectis Pharma Employees
Nuvectis Pharma had 13 employees as of September 30, 2025. The number of employees did not change compared to the same quarter last year.
Employees
13
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,138,846
Market Cap
215.17M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 13 | 0 | - |
| Jun 30, 2025 | 13 | 0 | - |
| Mar 31, 2025 | 13 | 0 | - |
| Dec 31, 2024 | 13 | 0 | - |
| Sep 30, 2024 | 13 | 0 | - |
| Jun 30, 2024 | 13 | - | - |
| Dec 31, 2023 | 13 | 2 | 18.18% |
| Dec 31, 2022 | 11 | 3 | 37.50% |
| Dec 31, 2021 | 8 | - | - |
| Sep 30, 2021 | 6 | - | - |
| Jun 30, 2021 | 4 | - | - |
Related Stocks
Employee RankingsNVCT News
- 6 weeks ago - Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC - GlobeNewsWire
- 2 months ago - Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC - GlobeNewsWire
- 3 months ago - CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights - GlobeNewsWire
- 3 months ago - Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - GlobeNewsWire
- 5 months ago - Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 6 months ago - Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900 - GlobeNewsWire
- 6 months ago - Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights - GlobeNewsWire
- 6 months ago - Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study - GlobeNewsWire